SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Discussion centers on reports that Nvidias board may remove Jensen Huang, alongside widespread but unverified claims that he has resigned amid affair allegations and scrutiny over possible China-related compliance issues. Traders debate the leadership and governance risk, with some fearing damage to Nvidias AI business and others arguing its fundamentals remain intact and treating the selloff as a buying opportunity.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius strong quarterly results are being overshadowed by a softer near-term outlook, delayed capacity ramp, and sharply higher capital spending, which traders fear could pressure funding and lead to dilution. Bulls point to robust AI-cloud demand and customer prepayments, while bears focus on execution and the cost of expansion.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondass quarterly results and higher revenue outlook are driving attention, with traders highlighting stronger sales, a larger backlog and an earlier profitability timeline. The reaction is split: bullish traders see accelerating defense-business growth and potential short covering, while skeptics point to margin pressure, widening operating losses, cash burn and dilution concerns.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines quarterly results beat expectations, with traders highlighting positive free cash flow and a record backlog; the NASA CLPS 2 selection is also part of the bullish backdrop. Bulls see evidence of improving execution, while skeptics point to ongoing losses, dilution and the need to convert backlog into billings.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors rally is driven by anticipation of the FDA decision on deramiocel for Duchenne muscular dystrophy, with the application focused on preserving upper-limb function; managements confidence and analyst upgrades have added to optimism. Traders are debating the binary outcomesome expect approval and a squeeze, while others point to the earlier advisory-panel vote and continued regulatory uncertainty.

Figure Technology Solutions, Inc. is a blockchain-native capital marketplace, which engages in connecting origination, funding, and secondary market activity. It operates through the following segments: FTI, Markets, and Other. The FTI segment offers Figure Connect which generates ecosystem and technology fees, and originates, sells, and securitizes home equity line of credit (HELOC) loans that it services. The Markets segment utilizes blockchain technology to develop an exchange for digital assets and credit, with new product offerings including providing interest-bearing stable coin deposits. The company was founded by Michael Scott Cagney and June Ou in 2018 and is headquartered in Reno, NV.

Figure Technology Solutions Inc. - Ordinary Shares - Class A

Figure Technology Solutions Inc

Figures Q3 earnings beat revenue and EPS expectations, and traders also highlighted an increased share-buyback authorization. The reaction is broadly bullish on the results and operating leverage, though some traders were disappointed by the lack of stronger guidance and remain focused on take-rate concerns and volatile, short-heavy trading.

Boost Run, Inc. is a provider of scalable cloud infrastructure purpose-built for enterprise AI and high-performance computing workloads. The platform delivers GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. The company was founded on September 5, 2025 and is headquartered in Northbrook, IL.

Boost Run Inc. - Ordinary Shares - Class A

Boost Run Inc.

BRUN is drawing attention around its Q3 results: revenue grew sharply year over year but missed expectations, prompting traders to question whether its large contracted backlog can translate into sustained revenue and profitability. Bulls point to contract growth and financing progress, while skeptics focus on the miss and execution risks.

ERock, Inc. operates, designs, and installs distributed generation power systems. The firm primarily serves data centers, utilities, commercial and industrial businesses. The company was founded on 2006 and is headquartered in Houston, TX.

ERock Inc. - Ordinary Shares - Class A

ERocks Q3 results are drawing attention, with traders highlighting a return to profitability, strong revenue growth, an expanded backlog, and reaffirmed full-year guidance. Many see the results as validation of its natural-gas microgrid role in powering AI data centers, while others remain wary of volatility, short interest, and execution risks.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

A hotter-than-expected CPI print has lifted Treasury yields and the dollar, while traders price in a more hawkish Fed outlook, pressuring gold and GLD. The selloff has prompted bearish calls for further declines, though some investors are buying the dip and looking for a rebound.

Cardinal Infrastructure Group, Inc. provides infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. It delivers wet utility installations of water, sewer, and stormwater systems, as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services. The company was founded on June 12, 2025 and is headquartered in Raleigh, NC.

Cardinal Infrastructure Group Inc - Ordinary Shares - Class A

Cardinals Q3 miss and withdrawal of its 2026 revenue and margin guidance, amid a sharp margin squeeze, are driving the selloff and discussion. Traders are split between calling the shares oversold and focusing on management credibility, the postponed Hughes Brothers deal, and whether the buyback can restore confidence.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corteva Posts Downbeat Q3 Results, Joins Nvidia, Alvotech And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. futures were mixed as Corteva plunged 8% after missing earnings and sales estimates; Digi, Nvidia, quantum stocks and others also fell premarket.read more...

Alvotech (ALVO) Reports Q3 Loss, Lags Revenue Estimates

Alvotech (ALVO) delivered earnings and revenue surprises of -200.00% and -18.62%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of +28.57% and +498.10%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Vericel Corporation (VCEL) Beats Q3 Earnings and Revenue Estimates

Vericel (VCEL) delivered earnings and revenue surprises of +1,250.00% and +9.03%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Will Alvotech (ALVO) Report Negative Earnings Next Week? What You Should Know

Alvotech (ALVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates

Repligen (RGEN) delivered earnings and revenue surprises of +15.22% and +1.30%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for October 21st

ALVO, CSIQ and AESI have been added to the Zacks Rank #5 (Strong Sell) List on October 21, 2026.

Futures Slip As Korean Data Center IPO Faceplant Revives Tech Rout, French Spread Blows Out

Futures Slip As Korean Data Center IPO Faceplant Revives Tech Rout, French Spread Blows Out

 US futures are lower, led by the Nasdaq, as Monday's AI relief bounce fizzled overnight after South Korean data-center firm Elice cratered more than 30% in its trading debut, reviving doubts...

ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside

Equity

Barclays analyst Glen Santangelo raised the stock to Overweight from Underweight and lifted his target to $8 from $4.


Napco Security Technologies Posts Upbeat Q4 Results, Joins Alvotech, Rum Group And Other Big Stocks Moving Higher On Monday

The text discusses recent gains in the stock market, particularly for companies like Napco Security Technologies and SuperX AI Technology. US stocks were mixed, with the Dow Jones index gaining 150 points. Napco Security Technologies rose after better-than-expected results. Other big gainers...

$ALVO Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.24 down -700.00% YoY
• Reported revenue of $111.6M down -2.02% YoY
• Alvotech maintains full-year 2026 guidance for total revenue of $650M and EBITDA of $180M, with performance now expected toward the lower end of the range.

Stocktwits

Alvotech

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.24 down -700.00% YoY
• Reported revenue of $111.6M down -2.02% YoY
• Alvotech maintains full-year 2026 guidance for total revenue of $650M and EBITDA of $180M, with performance now expected toward the lower end of the range.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of -$0.24 down -700.00% YoY
• Reported revenue of $111.6M down -2.02% YoY
• Alvotech maintains full-year 2026 guidance for total revenue of $650M and EBITDA of $180M, with performance now expected toward the lower end of the range.

Alvotech's nine-month adjusted revenue and gross margin were lower than the same period last year; full-year performance is expected toward guidance's lower end, and production and commercial supply continue ramping for planned fourth-quarter deliveries.

Alvotech reported FDA acceptance of AVT80's BLA and a first-known worldwide Eylea HD submission, approval of a Simlandi process more than doubling batch output, and Lotus commercialization rights.

https://files.quartr.com/streams/2026-11-12/1ed2c2da-65e3-4ec8-9f98-86084bba3f97/1/live_transcript.jsonl?ref=U3RvY2t0d2l0cw==

ALVO  Earnings Call

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Bullish Sentiment

<ul class="summary-bullets"><li>Santangelo now sees a favorable risk-reward into a cluster of U.S.Food and Drug Administration (FDA) decisions due by December 4 or sooner.</li><li>He states the stock, after a steep two-year slide from its 2024 peak near $18, offers around two times as much upside as downside on those rulings.</li><li>Alvotech is awaiting approval for its biosimilars to Johnson &amp; Johnson’s Simponi and Simponi Aria, Regeneron’s Eylea, and Amgen’s Prolia and Xgeva.</li></ul><p>Shares of Alvotech (ALVO) jumped about 8% intraday in U.S. trading on Wednesday after Barclays flipped its rating on the Icelandic biosimilar maker and doubled its price target, while voicing optimism about the U.S. Food and Drug Administration (FDA) approving three of its biosimilar programs.</p><p>Barclays analyst Glen Santangelo raised the stock to Overweight from Underweight and lifted his target to $8 from $4. The move is a reversal from March, when the same desk cut its target to $4 from $5 and said the shares will “remain in a holding pattern” ahead of the approvals.</p><p>Barclays’ new price target implies a potential upside of 59% from the stock’s closing price on Tuesday.</p><h2 class="st-heading-2">Why The Rating Flipped</h2><p>Santangelo now sees a favorable risk-reward into a cluster of FDA decisions due by December 4 or sooner. He states the stock, after a steep two-year slide from its 2024 peak near $18, offers around two times as much upside as downside on those rulings.</p><p>The firm pointed to work Alvotech completed after receiving letters from the FDA rejecting the applications last year. Those CRLs, tied to a 2025 pre-license inspection of the company’s Reykjavik plant, delayed proposed copies of Johnson &amp; Johnson’s Simponi and Simponi Aria, Regeneron’s Eylea, and Amgen’s Prolia and Xgeva. Alvotech resubmitted the applications in June.</p><h2 class="st-heading-2">Plant Inspection Closed</h2><p>Barclays’ confidence rests on a later, routine FDA surveillance inspection of the same Iceland facility. The agency finished that May audit and formally closed it in July with a Voluntary Action Indicated classification, a designation that typically means observations were noted but no enforcement action is planned. Alvotech has said the outcome supports its push to get the resubmitted filings approved this year.</p><h2 class="st-heading-2">What Is At Stake</h2><p>Alvotech develops and manufactures biosimilars and relies on partners to sell them. Teva handles U.S. marketing for the Simponi and Eylea candidates; Dr. Reddy’s is the U.S. applicant for the denosumab copies.</p><p>The company already sells U.S. biosimilars to AbbVie’s Humira and Johnson’s Stelara through Teva. Approvals on the pending files would widen that U.S. slate after a year defined by plant-related delays, leverage concerns, and a share-price low near $3 in June.</p><h2 class="st-heading-2">How Did ALVO Retail Traders React?</h2><p>On Stocktwits, retail sentiment around ALVO stock jumped from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume increased from ‘low’ to ‘normal’ levels.</p><p>A Stocktwits user said they are buying the stock, adding the stock has cleanly punched through a price ceiling that had been holding it back.</p><p><stembedurl>https://stocktwits.com/IrenGlazer69/message/664366053</stembedurl></p><p>Another user saw the stock hitting as high as $8 in 2027.</p><p><stembedurl>https://stocktwits.com/JohnTill/message/664363635</stembedurl></p><p><a href="https://stocktwits.com/symbol/ALVO">ALVO stock</a> has gained 6% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/not-a-gangbusters-launch-arrowhead-predicts-slow-burn-to-3-4-b-peak-for-redemplo-highlights-massive-pipeline/cZtY8zlRBPm">Not A ‘Gangbusters Launch’ — Arrowhead Predicts Slow Burn to $3-$4B Peak For Redemplo, Highlights ‘Massive Pipeline’</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Alvotech logo is seen displayed on a smartphone screen

Barclays analyst Glen Santangelo raised the stock to Overweight from Underweight and lifted his target to $8 from $4.

iShares Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$4.92
Prev Close	$4.88
Open	$4.94
Dividend Yield	0.00%
50-Day Moving Average	$5.27
Beta	0.75
Avg. Volume	952,662.01
PE Ratio	-8.83

52-Week High	$6.53
52-Week Low	$2.94
Market Capitalization	$1.92B
EPS (Annual)	$0.0964
Price to Book	-9.17
Revenue Per Employee	$401,589.73

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALVO Fundamentals